Your browser doesn't support javascript.
loading
CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.
Engeland, Christine E; Grossardt, Christian; Veinalde, Ruta; Bossow, Sascha; Lutz, Diana; Kaufmann, Johanna K; Shevchenko, Ivan; Umansky, Viktor; Nettelbeck, Dirk M; Weichert, Wilko; Jäger, Dirk; von Kalle, Christof; Ungerechts, Guy.
Afiliação
  • Engeland CE; 1] Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany [2] Department of Medical Oncology, National Center for Tumor Diseases and Heidelberg University Hospital, Heidelberg, Germany.
  • Grossardt C; Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany.
  • Veinalde R; Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany.
  • Bossow S; Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany.
  • Lutz D; Department of Pathology, University Hospital, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany.
  • Kaufmann JK; 1] German Cancer Research Center, Heidelberg, Germany [2] Current address: Harvey Cushing Neuro-Oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Maryland, USA.
  • Shevchenko I; 1] Skin Cancer Unit, German Cancer Research Center, Heidelberg, Germany [2] Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karls-University of Heidelberg, Heidelberg, Germany.
  • Umansky V; 1] Skin Cancer Unit, German Cancer Research Center, Heidelberg, Germany [2] Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karls-University of Heidelberg, Heidelberg, Germany.
  • Nettelbeck DM; German Cancer Research Center, Heidelberg, Germany.
  • Weichert W; Department of Pathology, University Hospital, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany.
  • Jäger D; Department of Medical Oncology, National Center for Tumor Diseases and Heidelberg University Hospital, Heidelberg, Germany.
  • von Kalle C; Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany.
  • Ungerechts G; 1] Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany [2] Department of Medical Oncology, National Center for Tumor Diseases and Heidelberg University Hospital, Heidelberg, Germany.
Mol Ther ; 22(11): 1949-59, 2014 Nov.
Article em En | MEDLINE | ID: mdl-25156126
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Melanoma Experimental / Linfócitos do Interstício Tumoral / Vírus Oncolíticos / Antígeno B7-H1 / Antígeno CTLA-4 Limite: Animals Idioma: En Revista: Mol Ther Assunto da revista: BIOLOGIA MOLECULAR / TERAPEUTICA Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Melanoma Experimental / Linfócitos do Interstício Tumoral / Vírus Oncolíticos / Antígeno B7-H1 / Antígeno CTLA-4 Limite: Animals Idioma: En Revista: Mol Ther Assunto da revista: BIOLOGIA MOLECULAR / TERAPEUTICA Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Estados Unidos